IGF1 and breast carcinoma: Increased IGF-I signaling has also been linked to trastuzumab resistance in ErbB2 positive breast cancer [8] and blocking both the IGF-I receptor (IGF-IR) and the ErbB2 receptor (ErbB2-R) inhibits ErbB2 driven breast cancer cell growth [9].